Edgewise Therapeutics Inc

For the period ended Dec 31, 2024. Filed Mar 3, 2025.

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2024 · Filed Mar 3, 2025

EWTX$48.74+8.2%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

STATEMENTS OF AND STOCKHOLDERS’ EQUITY

STATEMENTS OF STOCKHOLDERS’ EQUITY

(In thousands, except share data)


· · · · · · · · · · Accumulated · · · · · ·
· · · · · · · · · · Other · · · · · ·
· · Common Stock · · Additional · · Comprehensive · · Accumulated · · ·
· Shares · Amount · Paid-In Capital · Income (Loss) · Deficit · Total
Balance as of December 31, 2022	63,257,376	$6	$492,665	$(1,355)	$(144,600)	$346,716
Issuance of common stock, net of offering costs	6,928,044	1	52,549	—	—	52,550
Exercise of stock options and vesting of restricted stock units	172,663	—	117	—	—	117
Purchase of common stock under employee stock purchase plan	95,259	—	596	—	—	596
Stock-based compensation	—	—	17,560	—	—	17,560
Other comprehensive income	—	—	—	1,454	—	1,454
Net loss	—	—	—	—	(100,163)	(100,163)
Balance as of December 31, 2023	70,453,342	$7	$563,487	$99	$(244,763)	$318,830
Issuance of common stock, net of offering costs	22,450,206	2	238,797	—	—	238,799
Exercise of stock options and vesting of restricted stock units	1,787,832	—	9,480	—	—	9,480
Purchase of common stock under employee stock purchase plan	147,086	—	888	—	—	888
Stock-based compensation	—	—	24,711	—	—	24,711
Other comprehensive income	—	—	—	321	—	321
Net loss	—	—	—	—	(133,813)	(133,813)
Balance as of December 31, 2024	94,838,466	$9	$837,363	$420	$(378,576)	$459,216

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.